Loading...
XKRX092730
Market cap61mUSD
Jan 10, Last price  
11,530.00KRW
1D
-1.03%
1Q
-53.88%
Jan 2017
-55.82%
IPO
54.85%
Name

NeoPharm Co Ltd

Chart & Performance

D1W1MN
XKRX:092730 chart
P/E
3.88
P/S
0.93
EPS
2,968.15
Div Yield, %
6.07%
Shrs. gr., 5y
1.81%
Rev. gr., 5y
7.94%
Revenues
97.10b
+14.20%
18,774,371,84635,964,569,60242,368,623,34253,633,506,62866,274,581,62383,240,333,17181,625,347,55887,930,719,73185,033,138,23297,104,890,490
Net income
23.21b
+36.33%
647,762,9273,407,145,1377,742,493,66911,559,211,33715,369,685,34919,245,381,59218,130,855,34017,713,275,76017,027,039,73023,212,796,117
CFO
23.26b
+28.10%
564,344,7006,094,692,9139,156,579,73410,646,058,48216,179,233,44419,223,989,57017,073,759,98821,681,190,19818,160,509,70723,262,730,180
Dividend
Dec 27, 2023700 KRW/sh
Earnings
May 08, 2025

Profile

NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. Its products include emulsified and functional skin care products for sensitive and dry skin, treatment of atopic dermatitis and psoriasis, and therapy for steroid side effects. The company was founded on July 1, 2000 and is headquartered in Daejeon, South Korea.
URL
https://neopharm.co.kr/ko/default.do
IPO date
Jan 30, 2007
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
97,104,890
14.20%
85,033,138
-3.30%
Cost of revenue
71,797,586
53,622,767
Unusual Expense (Income)
NOPBT
25,307,305
31,410,371
NOPBT Margin
26.06%
36.94%
Operating Taxes
6,160,491
6,296,173
Tax Rate
24.34%
20.04%
NOPAT
19,146,813
25,114,198
Net income
23,212,796
36.33%
17,027,040
-3.87%
Dividends
(5,474,440)
(5,474,440)
Dividend yield
2.71%
3.65%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
635,251
393,576
Long-term debt
1,477,666
393,576
Deferred revenue
Other long-term liabilities
57,732
Net debt
(114,560,894)
(124,874,905)
Cash flow
Cash from operating activities
23,262,730
18,160,510
CAPEX
(20,827,987)
(806,429)
Cash from investing activities
(16,352,773)
(8,799,679)
Cash from financing activities
(5,916,678)
(5,750,369)
FCF
(6,755,267)
24,406,201
Balance
Cash
111,990,009
113,485,361
Long term investments
4,683,802
12,176,695
Excess cash
111,818,567
121,410,400
Stockholders' equity
118,220,808
100,270,322
Invested Capital
49,330,416
38,556,351
ROIC
43.57%
63.98%
ROCE
15.70%
22.63%
EV
Common stock shares outstanding
7,821
7,821
Price
25,850.00
34.64%
19,200.00
-22.58%
Market cap
202,163,234
34.64%
150,156,058
-22.58%
EV
88,288,181
25,281,153
EBITDA
26,980,488
32,974,181
EV/EBITDA
3.27
0.77
Interest
21,323
8,843
Interest/NOPBT
0.08%
0.03%